Reconsideración del rituximab en neuroinmunología: eficacia en el mundo real, rentabilidad y remisión a largo plazo

This short communication reviews the long-term use of rituximab (RTX) in neuroimmunological disease and presents a case of chronic inflammatory demyelinating polyneuropathy (CIDP) achieving sustained remission after rituximab therapy. A 10-year retrospective review of 40 patients treated with RTX at a South African quaternary neurology unit demonstrated consistent efficacy, durable safety, and significant cost savings compared to conventional immunotherapies. In addition, a patient with refractory childhood-onset CIDP achieved complete and enduring remission following RTX administration, with normal functional recovery and discontinuation of all immunotherapy. This report highlights the clinical and economic rationale for RTX as a long-term disease-modifying therapy in immune-mediated neurological disorders and argues for its earlier integration into standard treatment protocols, especially in resource-limited settings.